Document Detail

High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients.
MedLine Citation:
PMID:  10193946     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: In this study, the authors reviewed long term results and prognostic factors of high dose chemotherapy (HDC) with autologous stem cell support administered to 105 patients with epithelial ovarian carcinoma. METHODS: Prior to HDC, platinum-based chemotherapy was given to optimize (n = 94) and/or to mobilize peripheral blood stem cells (n = 33). After maximum debulking surgery, HDC with stem cell support was given; it consisted of cyclophosphamide, doxoribicin, and cisplatin (Regimen A, administered to 58 patients) or cyclophosphamide and carboplatin (Regimen B, administered to 47 patients). RESULTS: Five-year overall and disease free survival (OS, DFS) rates (%) according to stage were IC: 92.3, 92.3; II: 73.3, 73.3; III: 58.1, 35.7; IV: 33.7, 22.6; relapsed: 37.5, 31.0; OS, DFS at 8 years were IC: 92.3, 92.3; II: 73.3, 73.3; III: 48.8, 31.7; IV: 33.7, 22.6; relapsed: 37.5, 31.0. There was no difference in survival between patients who received Regimens A and B despite an increase in the total dose of platinum and an increase of more than 1.5- to 3.5-fold in the platinum course of HDC in Regimen B from the equivalence ratio of 4:1 between carboplatin and cisplatin. Among 65 Stage III and IV patients, the best results were obtained for 35 patients with small volume disease: 5-year OS, DFS rates were 74.3, 51.6, and 8-year OS, DFS rates were 66.4, 46.3. CONCLUSIONS: Good long term results were obtained with HDC. Small volume residual disease, platinum sensitivity, and histology excluding mucinous and clear cell adenocarcinoma were important factors for better survival. However, because the results were obtained for selected patients, a prospective, randomized study comparing HDC and standard chemotherapy is necessary if any definitive conclusions are to be drawn.
T Shinozuka; T Miyamoto; T Muramatsu; T Hirasawa; M Murakami; T Makino; Y Tanaka
Related Documents :
8131636 - Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancer.
16115936 - Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with a...
10826316 - Management of patients with cancer of unknown primary site.
9073306 - Treatment of advanced seminoma: an update.
18549626 - Clinical and prognostic analysis of 125 cases of non-hodgkin's lymphoma.
20525266 - Prognostic relevance of alt-associated markers in liposarcoma: a comparative analysis.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer     Volume:  85     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-04-30     Completed Date:  1999-04-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1555-64     Citation Subset:  AIM; IM    
Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma, Clear Cell / pathology,  therapy
Adenocarcinoma, Mucinous / pathology,  therapy
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carboplatin / administration & dosage
Cisplatin / administration & dosage
Combined Modality Therapy
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Hematopoietic Stem Cell Transplantation*
Middle Aged
Ovarian Neoplasms / mortality,  therapy*
Survival Rate
Transplantation, Autologous
Treatment Outcome
Reg. No./Substance:
15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; 41575-94-4/Carboplatin; 50-18-0/Cyclophosphamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with S...
Next Document:  Squamous cell carcinoma of the penis and microscopic pathologic margins: how much margin is needed f...